Follicular Lymphoma Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1067333
  • December 2021
  • Pharmaceuticals
  • 211 Pages
Report Description

This report is a comprehensive study that examines the Follicular Lymphoma industry in depth. With reference to key regions and major nations, the study specifies the product type of Follicular Lymphoma as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Follicular Lymphoma market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Follicular Lymphoma market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.

The top vendors and distributors operating in all of the major regions have also been highlighted in the Follicular Lymphoma market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
 
Follicular Lymphoma Market Strategic Analysis 

The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Follicular Lymphoma market study. The market dynamics and factors such as the threat of a Follicular Lymphoma substitute, the threat of new entrants into the Follicular Lymphoma market, buyer bargaining power, supplier bargaining power to Follicular Lymphoma providing companies, and internal rivalry among Follicular Lymphoma providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.

This analysis assists report users in evaluating the Follicular Lymphoma market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Follicular Lymphoma industry.
 
Follicular Lymphoma Market Key Trends Analysis

The important factors influencing the growth of the Follicular Lymphoma market have been examined in this report. The driving factors that are boosting demand for Follicular Lymphomas and the restraining factors that are slowing growth of the Follicular Lymphoma industry are addressed in depth, as well as their implications for the worldwide Follicular Lymphoma market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.

Follicular Lymphoma Market Key Segment Analysis

By segmenting the market by product type, application, and geography, the study provides a clear picture of the Follicular Lymphoma industry. On the basis of current and future trends, all segments of the Follicular Lymphoma industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.

The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.

The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
 
Follicular Lymphoma Market Regional Trends and Market Player’s Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Follicular Lymphoma market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Follicular Lymphoma market throughout the projected period.


 
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Follicular Lymphoma market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Follicular Lymphoma market. All important stakeholders in the Follicular Lymphoma value chain and technological ecosystem are expected to benefit from the insights offered in the Follicular Lymphoma market research study.

In order to provide a broader understanding of the top competitors in the Follicular Lymphoma market, the research includes a company market share analysis. AbbVie, ADC Therapeutics, Bayer Healthcare Pharmaceuticals, BeiGene, Bristol Myers Squibb, Epizyme|Eisai, Gilead Sciences, Incyte Corporation, Janssen Research & Development, MEI Pharma, MorphoSys, Nordic Nanovector, Novartis, Regeneron Pharmaceuticals are among the major participants in the global Follicular Lymphoma industry.
 
Scope of the report
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2021
Forecast Period Covered 2021-2028
Units for value Revenue in USD million and CAGR from 2021 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered AbbVie, ADC Therapeutics, Bayer Healthcare Pharmaceuticals, BeiGene, Bristol Myers Squibb, Epizyme|Eisai, Gilead Sciences, Incyte Corporation, Janssen Research & Development, MEI Pharma, MorphoSys, Nordic Nanovector, Novartis, Regeneron Pharmaceuticals
 
Major Highlights of the Follicular Lymphoma Market report study:
  • An in-depth examination of the global Follicular Lymphoma industry will be published soon.
  • The study examines the global Follicular Lymphoma market and offers major actionable information to its players.
  • The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
  • The report study is expected to aid the industry's key decision-makers in their decision-making process.
  • Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
  • The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Follicular Lymphoma industry.
  • The Market Ecosystem and Adoption in Different Markets
  • The global Follicular Lymphoma market is being shaped by several major trends.
  • The size of the Follicular Lymphoma market in terms of revenue has been measured in the past and will be measured in the future in USD million.
  • Consumer preference patterns and recent industrial developments
  • The worldwide Follicular Lymphoma market's competitive landscape and player positioning analysis
  • Major players' key goods and solutions, as well as their business strategies
  • Recommendations for new market entrants as well as existing market participants.
  • The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
  • Operating players in the market encounter a number of significant hurdles.
  • An examination of the major risks involved in market operations
 
The report segment of the global Follicular Lymphoma market as follows:
Global Follicular Lymphoma Market: By Product Type

  • Type I
  • Type II
  • Type III

Global Follicular Lymphoma Market: By Application
  • Application I
  • Application II
  • Application III

Global Follicular Lymphoma Market: By Region
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China 
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The report study is drafted to provide actionable insights to the following mentioned audience:
  • Institutes of research and consulting firms
  • Companies are attempting to get into the Follicular Lymphoma market.
  • Universities and students
  • Other companies in the Follicular Lymphoma market include solution providers, product producers, service providers, and others.
  • Private companies and government agencies that are linked
  • Individuals interested in learning more about the Follicular Lymphoma market

Manufacturers and Segments

  • AbbVie
  • ADC Therapeutics
  • Bayer Healthcare Pharmaceuticals
  • BeiGene
  • Bristol Myers Squibb
  • Epizyme|Eisai
  • Gilead Sciences
  • Incyte Corporation
  • Janssen Research & Development
  • MEI Pharma
  • MorphoSys
  • Nordic Nanovector
  • Novartis
  • Regeneron Pharmaceuticals
  • Type I
  • Type II
  • Type III
  • Application I
  • Application II
  • Application III

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Follicular Lymphoma Market Snapshot
          2.1.1. Global Follicular Lymphoma Market By Type I,2019
               2.1.1.1.
               2.1.1.2.Type I I
               2.1.1.3.Type I II
          2.1.2. Global Follicular Lymphoma Market By Application I,2019
               2.1.2.1.
               2.1.2.2.Application I I
               2.1.2.3.Application I II
          2.1.3. Global Follicular Lymphoma Market By End-use,2019
          2.1.4. Global Follicular Lymphoma Market By Geography,2019

3. Global Follicular Lymphoma Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Follicular Lymphoma Market Size (US$), By Type I, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type I, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type I, 2020
     4.2. Global Follicular Lymphoma Market Size (US$), By Type I, 2018 – 2028

5. Global Follicular Lymphoma Market Size (US$), By Application I, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application I, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application I, 2020
     5.2. Global Follicular Lymphoma Market Size (US$), By Application I, 2018 – 2028

6. Global Follicular Lymphoma Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Follicular Lymphoma Market Size (US$), By End-use, 2018 – 2028

7. Global Follicular Lymphoma Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Follicular Lymphoma Market Analysis, 2018 – 2028 
          7.2.1. North America Follicular Lymphoma Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Follicular Lymphoma Market Size (US$), By Type I, 2018 – 2028
          7.2.3. North America Follicular Lymphoma Market Size (US$), By Application I, 2018 – 2028
          7.2.4. North America Follicular Lymphoma Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Follicular Lymphoma Market Analysis, 2018 – 2028 
          7.3.1.  Europe Follicular Lymphoma Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Follicular Lymphoma Market Size (US$), By Type I, 2018 – 2028
          7.3.3. Europe Follicular Lymphoma Market Size (US$), By Application I, 2018 – 2028
          7.3.4. Europe Follicular Lymphoma Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Follicular Lymphoma Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Follicular Lymphoma Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Follicular Lymphoma Market Size (US$), By Type I, 2018 – 2028
          7.4.3. Asia Pacific Follicular Lymphoma Market Size (US$), By Application I, 2018 – 2028
          7.4.4. Asia Pacific Follicular Lymphoma Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Follicular Lymphoma Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Follicular Lymphoma Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Follicular Lymphoma Market Size (US$), By Type I, 2018 – 2028
          7.5.3. Latin America Follicular Lymphoma Market Size (US$), By Application I, 2018 – 2028
          7.5.4. Latin America Follicular Lymphoma Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Follicular Lymphoma Market Analysis, 2018 – 2028 
          7.6.1.  MEA Follicular Lymphoma Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Follicular Lymphoma Market Size (US$), By Type I, 2018 – 2028
          7.6.3. MEA Follicular Lymphoma Market Size (US$), By Application I, 2018 – 2028
          7.6.4. MEA Follicular Lymphoma Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Follicular Lymphoma Providers
        8.4.1 AbbVie
                8.4.1.1 Business Description
                8.4.1.2 AbbVie Geographic Operations
                8.4.1.3 AbbVie Financial Information
                8.4.1.4 AbbVie Product Positions/Portfolio
                8.4.1.5 AbbVie Key Developments
        8.4.2 ADC Therapeutics
                8.4.2.1 Business Description
                8.4.2.2 ADC Therapeutics Geographic Operations
                8.4.2.3 ADC Therapeutics Financial Information
                8.4.2.4 ADC Therapeutics Product Positions/Portfolio
                8.4.2.5 ADC Therapeutics Key Developments
        8.4.3 Bayer Healthcare Pharmaceuticals
                8.4.3.1 Business Description
                8.4.3.2 Bayer Healthcare Pharmaceuticals Geographic Operations
                8.4.3.3 Bayer Healthcare Pharmaceuticals Financial Information
                8.4.3.4 Bayer Healthcare Pharmaceuticals Product Positions/Portfolio
                8.4.3.5 Bayer Healthcare Pharmaceuticals Key Developments
        8.4.4 BeiGene
                8.4.4.1 Business Description
                8.4.4.2 BeiGene Geographic Operations
                8.4.4.3 BeiGene Financial Information
                8.4.4.4 BeiGene Product Positions/Portfolio
                8.4.4.5 BeiGene Key Developments
        8.4.5 Bristol Myers Squibb
                8.4.5.1 Business Description
                8.4.5.2 Bristol Myers Squibb Geographic Operations
                8.4.5.3 Bristol Myers Squibb Financial Information
                8.4.5.4 Bristol Myers Squibb Product Positions/Portfolio
                8.4.5.5 Bristol Myers Squibb Key Developments
        8.4.6 Epizyme|Eisai
                8.4.6.1 Business Description
                8.4.6.2 Epizyme|Eisai Geographic Operations
                8.4.6.3 Epizyme|Eisai Financial Information
                8.4.6.4 Epizyme|Eisai Product Positions/Portfolio
                8.4.6.5 Epizyme|Eisai Key Developments
        8.4.7 Gilead Sciences
                8.4.7.1 Business Description
                8.4.7.2 Gilead Sciences Geographic Operations
                8.4.7.3 Gilead Sciences Financial Information
                8.4.7.4 Gilead Sciences Product Positions/Portfolio
                8.4.7.5 Gilead Sciences Key Developments
        8.4.8 Incyte Corporation
                8.4.8.1 Business Description
                8.4.8.2 Incyte Corporation Geographic Operations
                8.4.8.3 Incyte Corporation Financial Information
                8.4.8.4 Incyte Corporation Product Positions/Portfolio
                8.4.8.5 Incyte Corporation Key Developments
        8.4.9 Janssen Research & Development
                8.4.9.1 Business Description
                8.4.9.2 Janssen Research & Development Geographic Operations
                8.4.9.3 Janssen Research & Development Financial Information
                8.4.9.4 Janssen Research & Development Product Positions/Portfolio
                8.4.9.5 Janssen Research & Development Key Developments
        8.4.10 MEI Pharma
                8.4.10.1 Business Description
                8.4.10.2 MEI Pharma Geographic Operations
                8.4.10.3 MEI Pharma Financial Information
                8.4.10.4 MEI Pharma Product Positions/Portfolio
                8.4.10.5 MEI Pharma Key Developments
        8.4.11 MorphoSys
                8.4.11.1 Business Description
                8.4.11.2 MorphoSys Geographic Operations
                8.4.11.3 MorphoSys Financial Information
                8.4.11.4 MorphoSys Product Positions/Portfolio
                8.4.11.5 MorphoSys Key Developments
        8.4.12 Nordic Nanovector
                8.4.12.1 Business Description
                8.4.12.2 Nordic Nanovector Geographic Operations
                8.4.12.3 Nordic Nanovector Financial Information
                8.4.12.4 Nordic Nanovector Product Positions/Portfolio
                8.4.12.5 Nordic Nanovector Key Developments
        8.4.13 Novartis
                8.4.13.1 Business Description
                8.4.13.2 Novartis Geographic Operations
                8.4.13.3 Novartis Financial Information
                8.4.13.4 Novartis Product Positions/Portfolio
                8.4.13.5 Novartis Key Developments
        8.4.14 Regeneron Pharmaceuticals
                8.4.14.1 Business Description
                8.4.14.2 Regeneron Pharmaceuticals Geographic Operations
                8.4.14.3 Regeneron Pharmaceuticals Financial Information
                8.4.14.4 Regeneron Pharmaceuticals Product Positions/Portfolio
                8.4.14.5 Regeneron Pharmaceuticals Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Follicular Lymphoma Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Follicular Lymphoma Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Follicular Lymphoma Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Follicular Lymphoma Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Follicular Lymphoma Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Follicular Lymphoma Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Follicular Lymphoma Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Follicular Lymphoma Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Follicular Lymphoma Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Follicular Lymphoma Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Follicular Lymphoma Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Follicular Lymphoma Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Follicular Lymphoma Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Follicular Lymphoma Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Follicular Lymphoma Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Follicular Lymphoma Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Follicular Lymphoma: Market Segmentation 
FIG. 2 Global Follicular Lymphoma Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Follicular Lymphoma Market, By Type I, 2019 (US$ Mn) 
FIG. 5 Global Follicular Lymphoma Market, By Application I, 2019 (US$ Mn) 
FIG. 6 Global Follicular Lymphoma Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Follicular Lymphoma Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Follicular Lymphoma Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Follicular Lymphoma Providers, 2019
FIG. 11 Global Follicular Lymphoma Market Revenue Contribution, By Type I, 2019 & 2028 (Value %) 
FIG. 12 Global Follicular Lymphoma Market Revenue Contribution, By Application I, 2019 & 2028 (Value %) 
FIG. 13 Global Follicular Lymphoma Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Follicular Lymphoma Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Follicular Lymphoma Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Follicular Lymphoma Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Follicular Lymphoma Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Follicular Lymphoma Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Follicular Lymphoma market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Follicular Lymphoma Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Follicular Lymphoma Market Value, By Segment1, 2018 – 2028
TABLE  North America Follicular Lymphoma Market Value, By Segment2, 2018 – 2028
TABLE  North America Follicular Lymphoma Market Value, By Country, 2018 – 2028
TABLE  Europe Follicular Lymphoma Market Value, By Segment1, 2018 – 2028
TABLE  Europe Follicular Lymphoma Market Value, By Segment2, 2018 – 2028
TABLE  Europe Follicular Lymphoma Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Follicular Lymphoma Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Follicular Lymphoma Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Follicular Lymphoma Market Value, By Country, 2018 – 2028
TABLE  Latin America Follicular Lymphoma Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Follicular Lymphoma Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Follicular Lymphoma Market Value, By Country, 2018 – 2028
TABLE  MEA Follicular Lymphoma Market Value, By Segment1, 2018 – 2028
TABLE  MEA Follicular Lymphoma Market Value, By Segment2, 2018 – 2028
TABLE  MEA Follicular Lymphoma Market Value, By Country, 2018 – 2028
TABLE  AbbVie: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ADC Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bayer Healthcare Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  BeiGene: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol Myers Squibb: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Epizyme|Eisai: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Gilead Sciences: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Incyte Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Janssen Research & Development: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  MEI Pharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  MorphoSys: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Nordic Nanovector: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Regeneron Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Follicular Lymphoma Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Follicular Lymphoma Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Follicular Lymphoma Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Follicular Lymphoma Market, By Geography, 2019 (US$ Mn)
FIG.  Global Follicular Lymphoma Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Follicular Lymphoma Providers, 2016
FIG.  Global Follicular Lymphoma Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Type I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type III Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Follicular Lymphoma Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Application I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application III Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Follicular Lymphoma Market Value, 2018 – 2028, (US$ Mn)